43 results
8-K
EX-99.1
DRMA
Dermata Therapeutics Inc
15 May 24
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:06pm
resources to be sufficient to fund operations into the third quarter of 2024.
Research and development expenses were $1.6 million for the quarter ended … March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023. The increase in research and development expense was the result
8-K
EX-99.1
DRMA
Dermata Therapeutics Inc
21 Mar 24
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
4:05pm
into the third quarter of 2024.
Research and development expenses were $4.1 million for the year ended December 31, 2023, compared to $5.7 million … for the year ended December 31, 2022. The decrease in research and development expense was the result of decreased clinical trial and non-clinical expenses
8-K
EX-99.1
blgurznk
9 Nov 23
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
s5z7pg2l
10 Aug 23
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter
4:18pm
424B5
tgt71tvxdck a650vc7
25 May 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
efq2y
11 May 23
Dermata Therapeutics Provides Corporate Update and Reports First Quarter
4:07pm
S-3
k1jv1hm9 66x8
15 Nov 22
Shelf registration
4:06pm
8-K
EX-99.1
pw0jnt 99
10 Nov 22
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
5:22pm
8-K
EX-99.1
5pmla5n1nlnoq1
15 Aug 22
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
4:20pm
DEF 14A
walmr0veaxwf2dzw
1 Jun 22
Definitive proxy
4:20pm
PRE 14A
a5xtgzw1
20 May 22
Preliminary proxy
4:05pm